These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 26738349)

  • 1. Plasma 8-isoPGF2α and serum melatonin levels in patients with minimal cognitive impairment and Alzheimer disease.
    Sirin FB; Kumbul Doğuç D; Vural H; Eren I; Inanli I; Sütçü R; Delibaş N
    Turk J Med Sci; 2015; 45(5):1073-7. PubMed ID: 26738349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peripheral oxidative stress biomarkers in mild cognitive impairment and Alzheimer's disease.
    Torres LL; Quaglio NB; de Souza GT; Garcia RT; Dati LM; Moreira WL; Loureiro AP; de Souza-Talarico JN; Smid J; Porto CS; Bottino CM; Nitrini R; Barros SB; Camarini R; Marcourakis T
    J Alzheimers Dis; 2011; 26(1):59-68. PubMed ID: 21593563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum Daytime Melatonin Levels Reflect Cerebrospinal Fluid Melatonin Levels in Alzheimer's Disease but Are Not Correlated with Cognitive Decline.
    Nous A; Wittens MMJ; Vermeiren Y; De Deyn PP; Van Broeckhoven C; Nagels G; Smolders I; Engelborghs S
    J Alzheimers Dis; 2021; 83(2):693-704. PubMed ID: 34366353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers for Early Diagnostic of Mild Cognitive Impairment in Type-2 Diabetes Patients: A Multicentre, Retrospective, Nested Case-Control Study.
    Xu ZP; Yang SL; Zhao S; Zheng CH; Li HH; Zhang Y; Huang RX; Li MZ; Gao Y; Zhang SJ; Zhan PY; Zhang LF; Deng L; Wei S; Liu YC; Ye JW; Ren HJ; Li N; Kong CX; Wang X; Fang L; Zhou QZ; Jiang HW; Li JR; Wang Q; Ke D; Liu GP; Wang JZ
    EBioMedicine; 2016 Mar; 5():105-13. PubMed ID: 27077117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood-based redox-signature and their association to the cognitive scores in MCI and Alzheimer's disease patients.
    Perrotte M; Le Page A; Fournet M; Le Sayec M; Rassart É; Fulop T; Ramassamy C
    Free Radic Biol Med; 2019 Jan; 130():499-511. PubMed ID: 30445127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The evaluation of thiol-disulfıte balance, ischemıa albumın modıfıcation and seruloplazmine as a new oxidatıve stress in mild cognitive impairment and early stage alzheimer's disease patients.
    Gündüztepe Y; Bukan N; Zorlu E; Karaman Y; Andaç Topkan T; Gurbuz N; Neşelioğlu S; Erel Ö
    J Clin Neurosci; 2020 May; 75():188-194. PubMed ID: 32223973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteomics based identification of differential plasma proteins and changes in white matter integrity as markers in early detection of mild cognitive impaired subjects at high risk of Alzheimer's disease.
    Kumar A; Singh S; Verma A; Mishra VN
    Neurosci Lett; 2018 May; 676():71-77. PubMed ID: 29649488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum levels of vitamin E forms and risk of cognitive impairment in a Finnish cohort of older adults.
    Mangialasche F; Solomon A; Kåreholt I; Hooshmand B; Cecchetti R; Fratiglioni L; Soininen H; Laatikainen T; Mecocci P; Kivipelto M
    Exp Gerontol; 2013 Dec; 48(12):1428-35. PubMed ID: 24113154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interrelationship between Mini-Mental State Examination scores and biochemical parameters in patients with mild cognitive impairment and Alzheimer's disease.
    Vasantharekha R; Priyanka HP; Swarnalingam T; Srinivasan AV; ThyagaRajan S
    Geriatr Gerontol Int; 2017 Oct; 17(10):1737-1745. PubMed ID: 27921357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What Are the Reliable Plasma Biomarkers for Mild Cognitive Impairment? A Clinical 4D Proteomics Study and Validation.
    Hou Z; Sun A; Li Y; Song X; Liu S; Hu X; Luan Y; Guan H; He C; Sun Y; Chen J
    Mediators Inflamm; 2024; 2024():7709277. PubMed ID: 38883967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasminogen activator inhibitor-1 as an early potential diagnostic marker for Alzheimer's disease.
    Oh J; Lee HJ; Song JH; Park SI; Kim H
    Exp Gerontol; 2014 Dec; 60():87-91. PubMed ID: 25304332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased Plasma Beta-Secretase 1 May Predict Conversion to Alzheimer's Disease Dementia in Individuals With Mild Cognitive Impairment.
    Shen Y; Wang H; Sun Q; Yao H; Keegan AP; Mullan M; Wilson J; Lista S; Leyhe T; Laske C; Rujescu D; Levey A; Wallin A; Blennow K; Li R; Hampel H
    Biol Psychiatry; 2018 Mar; 83(5):447-455. PubMed ID: 28359566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Systemic inflammatory markers in age-associated cognitive impairment and Alzheimer's disease].
    Kliushnik TP; Androsova LV; Mikhaylova NM; Kolykhalov IV; Zozulya SA; Dupin AM
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(7):74-79. PubMed ID: 28805765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma Homocysteine and Serum Folate and Vitamin B
    Ma F; Wu T; Zhao J; Ji L; Song A; Zhang M; Huang G
    Nutrients; 2017 Jul; 9(7):. PubMed ID: 28698453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chromosomal DNA damage measured using the cytokinesis-block micronucleus cytome assay is significantly associated with cognitive impairment in South Australians.
    Lee SL; Thomas P; Hecker J; Faunt J; Fenech M
    Environ Mol Mutagen; 2015 Jan; 56(1):32-40. PubMed ID: 25099033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relation of plasma selenium and lipid peroxidation end products in patients with Alzheimer's disease.
    Chmatalova Z; Vyhnalek M; Laczo J; Hort J; Pospisilova R; Pechova M; Skoumalova A
    Physiol Res; 2017 Dec; 66(6):1049-1056. PubMed ID: 28937243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vitamin D Increases Aβ140 Plasma Levels and Protects Lymphocytes from Oxidative Death in Mild Cognitive Impairment Patients.
    SanMartin CD; Henriquez M; Chacon C; Ponce DP; Salech F; Rogers NK; Behrens MI
    Curr Alzheimer Res; 2018; 15(6):561-569. PubMed ID: 29283046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma amyloid levels within the Alzheimer's process and correlations with central biomarkers.
    Hanon O; Vidal JS; Lehmann S; Bombois S; Allinquant B; Tréluyer JM; Gelé P; Delmaire C; Blanc F; Mangin JF; Buée L; Touchon J; Hugon J; Vellas B; Galbrun E; Benetos A; Berrut G; Paillaud E; Wallon D; Castelnovo G; Volpe-Gillot L; Paccalin M; Robert PH; Godefroy O; Dantoine T; Camus V; Belmin J; Vandel P; Novella JL; Duron E; Rigaud AS; Schraen-Maschke S; Gabelle A;
    Alzheimers Dement; 2018 Jul; 14(7):858-868. PubMed ID: 29458036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. γH2AX is increased in peripheral blood lymphocytes of Alzheimer's disease patients in the South Australian Neurodegeneration, Nutrition and DNA Damage (SAND) study of aging.
    Siddiqui MS; Francois M; Hecker J; Faunt J; Fenech MF; Leifert WR
    Mutat Res Genet Toxicol Environ Mutagen; 2018; 829-830():6-18. PubMed ID: 29704994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression.
    Zetterberg H; Skillbäck T; Mattsson N; Trojanowski JQ; Portelius E; Shaw LM; Weiner MW; Blennow K;
    JAMA Neurol; 2016 Jan; 73(1):60-7. PubMed ID: 26524180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.